Healthcare & Medical Devices Global On demand · 24-48h

Global Exosome SEC Column Market Strategic Research Report

Global Exosome SEC Column Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Exosome SEC Column Market
$4992025
15%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Plasma/Serum Exosome SEC Column, Cell Culture Media SEC Column, Urine Exosome SEC Column, Multi-sample Universal SEC Column

By Application: Pharmaceutical, Clinical, Research, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Cytiva, Thermo Fisher Scientific, Merck Kgaa, Danaher Corporation, Bio-Rad Laboratories, Agilent Technologies, Waters Corporation, Tosoh Bioscience, Shimadzu Corporation, Izon Science, Nanoeast Biotechnology, Beijing Origene Technologies, Shanghai Excell Bio, Sepax Technologies, Sartorius AG, Repligen Corporation, Phenomenex, Purolite, Shimadzu Bio-Science Division, Bio-Techne Corporation

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 134 pages
Market size 2025
$499
Million USD
Forecast CAGR
15%
2025-2032
Forecast 2032
$1327.3
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Exosome SEC Column market size is predicted to grow from US$ 499 million in 2025 to US$ 1,325 million in 2032; it is expected to grow at a CAGR of 15.0% from 2026 to 2032.

An Exosome SEC Column (Size Exclusion Chromatography Column) is a chromatographic tool specifically designed to isolate and purify exosomes based on their size. It separates particles by allowing smaller molecules (such as proteins and salts) to enter the porous matrix inside the column and be retained longer, while larger vesicles like exosomes are excluded from the pores and elute earlier. This method preserves the structural integrity and biological activity of exosomes, making it widely used in extracellular vesicle research and downstream applications.In 2025, global Exosome SEC Column production reached approximately 2.43 M units, with an average global market price of around US$ 210 per unit. Annual production capacity is 2.95 M units. Gross Profit Margin: 68%.The Exosome SEC Column industry chain is structured into three main layers. The upstream segment includes chromatography resin and material suppliers such as agarose, dextran, and polymer bead manufacturers, which determine the core separation performance of the column. The midstream consists of SEC column manufacturers and EV isolation kit developers who design, pack, and validate the final products for laboratory and clinical use. The downstream includes pharmaceutical companies, CROs, academic research institutes, and diagnostic laboratories that apply SEC columns for exosome purification, biomarker discovery, and liquid biopsy workflows.Exosome SEC Columns represent a high-growth but structurally specialized niche within the broader life science tools industry. Their value lies not in high unit volume but in increasing adoption in EV-based diagnostics and therapeutic development. In my view, the market is still transitioning from research-use dominance toward early clinical and industrial applications, meaning standardization and scalability will be the key drivers of long-term competition rather than price alone.

Global key Exosome SEC Column players cover Cytiva, Thermo Fisher Scientific, Merck Kgaa, Danaher Corporation, Bio-Rad Laboratories, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Exosome SEC Column market?

What factors are driving Exosome SEC Column market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Exosome SEC Column market opportunities vary by end market size?

How does Exosome SEC Column break out by Processing Capacity, by Application?

This report presents a comprehensive overview of the global Exosome SEC Column market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Sample Type

  • Plasma/Serum Exosome SEC Column
  • Cell Culture Media SEC Column
  • Urine Exosome SEC Column
  • Multi-sample Universal SEC Column

Segment by Processing Capacity

  • Micro-scale SEC Column (<1 mL sample)
  • Small-scale SEC Column (1–10 mL sample)
  • Medium-scale SEC Column (10–100 mL sample)
  • Large-scale SEC Column (>100 mL sample)

Segment by Column Format

  • Spin Column
  • Gravity Column
  • FPLC Column

Segment by Application

  • Pharmaceutical
  • Clinical
  • Research
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Exosome SEC Column market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pharmaceutical, Clinical, Research evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Exosome SEC Column Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15%
Regional growth momentum
Market share by segment
Key metrics
Base value
$499
2025
Forecast
$1327.3
2032
CAGR
15%
2025–2032
Regiões
5
global
Key companies
CytivaThermo Fisher ScientificMerck KgaaDanaher CorporationBio-Rad LaboratoriesAgilent TechnologiesWaters CorporationTosoh Bioscience
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Plasma/Serum Exosome SEC ColumnCell Culture Media SEC ColumnUrine Exosome SEC ColumnMulti-sample Universal SEC Column
By Application
PharmaceuticalClinicalResearchOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Plasma/Serum Exosome SEC Column
  • 3.1.3 Cell Culture Media SEC Column
  • 3.1.4 Urine Exosome SEC Column
  • 3.1.5 Multi-sample Universal SEC Column
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pharmaceutical
  • 4.1.3 Clinical
  • 4.1.4 Research
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Cytiva
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Merck Kgaa
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Danaher Corporation
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Bio-Rad Laboratories
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Agilent Technologies
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Waters Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Tosoh Bioscience
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Shimadzu Corporation
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Izon Science
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Nanoeast Biotechnology
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Beijing Origene Technologies
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Shanghai Excell Bio
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Sepax Technologies
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Sartorius AG
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Repligen Corporation
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Phenomenex
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Purolite
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Shimadzu Bio-Science Division
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Bio-Techne Corporation
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Exosome SEC Column market?
The global Exosome SEC Column market is estimated at US$ 499 million in 2025 (base year) and is projected to reach US$ 1.32 billion by 2032.
What is the forecast CAGR for the Exosome SEC Column market?
The market is expected to grow at a CAGR of 15.0% from 2026 to 2032, expanding from US$ 499 million in 2025 to US$ 1.32 billion in 2032, roughly 2.6 times its base-year value.
What is Exosome SEC Column?
An Exosome SEC Column (Size Exclusion Chromatography Column) is a chromatographic tool specifically designed to isolate and purify exosomes based on their size. It separates particles by allowing smaller molecules (such as proteins and salts) to enter the porous matrix inside the column and be retained longer, while larger vesicles like exosomes are excluded from the pores and elute earlier.
What are the main segments of the Exosome SEC Column market by sample type?
By sample type, the market is segmented into Plasma/Serum Exosome SEC Column, Cell Culture Media SEC Column, Urine Exosome SEC Column and Multi-sample Universal SEC Column.
Which applications drive demand in the Exosome SEC Column market?
Key applications covered include Pharmaceutical, Clinical, Research and Others.
Who are the key players in the Exosome SEC Column market?
Key players profiled include Cytiva, Thermo Fisher Scientific, Merck Kgaa, Danaher Corporation, Bio-Rad Laboratories, Agilent Technologies, Waters Corporation and Tosoh Bioscience, among 20 companies covered in total.
Which regions and countries are covered for Exosome SEC Column?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Exosome SEC Column market?
What factors are driving Exosome SEC Column market growth, globally and by region?
Who should buy the Exosome SEC Column market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pharmaceutical, Clinical and Research, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Exosome SEC Column market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.